Use of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR) for prognostication of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT): a systematic review
- 28 Downloads
Background and purpose
The neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios are markers of systemic inflammation with uncertain prognostic utility. Thus, we conducted a systematic review of NLR and PLR as prognostic factors for overall survival (OS), progression-free survival (PFS), and local control (LC) of patients with stage 1 non-small cell lung cancer (NSCLC) following stereotactic body radiotherapy (SBRT) with curative intent.
Methods and materials
The EMBASE, Cochrane Library, MEDLINE, and PubMed databases were searched from January 1996 until September 2017 for primary research studies and systematic literature reviews that reported pre-treatment NLR and PLR of patients with stage 1 NSCLC and OS, PFS, and/or LC of patients following SBRT.
An electronic database search identified 292 articles, of which five were eligible for inclusion. Cutoffs for a high NLR ranged from 2.18 to 3.155 while cutoffs for a high PLR ranged from 146 to 187.27. Four studies reported outcomes related to disease control and had mixed results as to the utility of the NLR and PLR as a prognostic factor. Four studies analyzed the association between high NLR cutoff with OS and all found a statistically significant association. Three studies examined a high PLR cutoff and all found a statistically significant association with worse OS.
NLR and PLR appear to be relevant prognostic factors for OS following lung SBRT in stage I NSCLC. They may serve as accessible and inexpensive tests to aid in clinical decision-making but prospective validation is necessary.
KeywordsCarcinoma Non-small cell lung Radiosurgery Radiotherapy Conformal Review Systematic Neutrophil to lymphocyte ratio Platelet to lymphocyte ratio Inflammation Prognosis
Neutrophil to lymphocyte ratio
Platelet to lymphocyte ratio
Compliance with ethical standards
No funding was received for this study.
Conflict of interest
Dr. Meredith Giuliani declares funding from Elekta Inc. and AstraZeneca that is unrelated to this work. Dr. Swaminath declares an educational grant from Accuray and advisory board membership from AstraZeneca that is unrelated to this work. Daegan Sit, Thomas Raissi, Percy Lee, Narek Shaverdian, and Cindy Walker-Dilks declare no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Statement of informed consent was not applicable since the manuscript does not contain any patient data.
- 8.Trovo M, Giaj-Levra N, Furlan C, Bortolin MT, Muraro E, Polesel J, Minatel E, Tedeschi R, Filippi AR, Alongi F, Ricardi U (2016) Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study. Clin Transl Oncol 18:1003–1010CrossRefGoogle Scholar
- 15.Bazan JG, Allan E, Washington I, Majithia L, Grecula JC, Haglund KE et al (2015) Increased pretreatment neutrophil-to-lymphocyte ratios and platelet-to-lymphocyte ratios are independent prognostic markers for worse overall survival in patients receiving concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 1:E440CrossRefGoogle Scholar
- 17.Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M et al (2017) Long-term outcomes of salvage stereotactic ablative radiotherapy for isolated lung recurrence of non-small cell lung cancer: a phase II clinical trial. J Thorac Oncol 06Google Scholar
- 22.Arbel Y, Finkelstein A, Halkin A, Birati EY, Revivo M, Zuzut M, Shevach A, Berliner S, Herz I, Keren G, Banai S (2012) Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis. 225:456–460CrossRefGoogle Scholar
- 23.Furuncuoglu Y, Tulgar S, Dogan AN, Cakar S, Tulgar YK, Cakiroglu B (2016) How obesity affects the neutrophil/lymphocyte and platelet/lymphocyte ratio, systemic immune-inflammatory index and platelet indices: a retrospective study. Eur Rev Med Pharmacol Sci 20:1300–1306Google Scholar
- 24.Louie AV, Haasbeek CJ, Mokhles S, Rodrigues GB, Stephans KL, Lagerwaard FJ et al (2015) Predicting overall survival after stereotactic ablative radiation therapy in early-stage lung cancer: development and external validation of the Amsterdam prognostic model. Int J Radiat Oncol Biol Phys 93:82–90CrossRefGoogle Scholar
- 26.Klement RJ, Belderbos J, Grills I, Werner-Wasik M, Hope A, Giuliani M, Ye H, Sonke JJ, Peulen H, Guckenberger M (2016) Prediction of early death in patients with early-stage NSCLC-can we select patients without a potential benefit of SBRT as a curative treatment approach? J Thorac Oncol 11:1132–1139CrossRefGoogle Scholar